🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

13 results for “iptacopan” Clear

  1. IPTACOPAN

    Novartis Ophthalmics Europe

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  2. IPTACOPAN

    Novartis Ophthalmics Europe

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  3. IPTACOPAN

    Novartis Ophthalmics Europe

    Atypical hemolytic uremic syndrome

    phase 3 small molecule active

    1 trial

  4. IPTACOPAN HYDROCHLORIDE

    Novartis Ophthalmics Europe

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  5. IPTACOPAN, LNP023

    Novartis Ophthalmics Europe

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  6. Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023 200 mg), IPTACOPAN

    Novartis Ophthalmics Europe

    IgA Nephropathy

    phase 3 small molecule active

    1 trial

  7. Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023), IPTACOPAN

    Novartis Ophthalmics Europe

    generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  8. Placebo 0 mg hard gelatin capsule size 1, (placebo to lnp023 100 mg), Placebo 0 mg hard gelatin capsule size 0, (placebo to lnp023 200 mg), IPTACOPAN HYDROCHLORIDE, IPTACOPAN

    Novartis Ophthalmics Europe

    complement 3 glomerulopathy

    phase 3 small molecule active

    1 trial

  9. IPTACOPAN, Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023)

    Novartis Ophthalmics Europe

    active antineutrophilic cytoplasmic antibody (ANCA) associated vasculitis

    phase 2 small molecule active

    1 trial

  10. MYCOPHENOLIC ACID , PREDNISONE, MYCOPHENOLATE SODIUM, PREDNISONE, MYCOPHENOLATE SODIUM, Placebo 0 mg hard gelatin capsule size 0 and size 2, (placebo to LNP023), METHYLPREDNISOLONE , IPTACOPAN, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, LNP023, Placebo to prednisone

    Novartis Ophthalmics Europe

    Lupus Nephritis Class III-IV, +/- V

    phase 2 small molecule active

    1 trial

  11. -, IPTACOPAN, -, -, -

    Novartis Ophthalmics Europe

    IgA Nephropathy

    approved small molecule active

    1 trial

  12. IPTACOPAN HYDROCHLORIDE, IPTACOPAN

    Novartis Ophthalmics Europe

    C3 Glomerulopathy or idiopathic immune-complex membranoproliferative glomerulonephritis

    approved small molecule active

    1 trial

  13. iptacopan

    First Tracks Biotherapeutics

    Thrombotic Microangiopathy

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources